Skip to content
DraconiticResearch
Search Sources API
197,788 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Current Heart Failure Reports

Don't Wait- Ablate! Catheter Ablation in Patients with Advanced Heart Failure and Atrial Fibrillation

  • Maximilian Moersdorf1,2
  • Philipp Sommer1,3
  • Christian Sohns1
  1. 1Department of Electrophysiology, Heart- and Diabetescenter NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany
  2. 2Tulane Research Innovation for Arrhythmia Discovery (TRIAD), Tulane University, New Orleans, LA USA
  3. 3Department of Electrophysiology, Heart- and Diabetescenter NRW, University Bielefeld, Medical Faculty OWL, Bad Oeynhausen, Germany
Read full textDOICite

Abstract

Purpose of Review: Heart failure (HF) and atrial fibrillation (AF) frequently coexist and mutually accelerate disease progression through complex hemodynamic, neurohormonal, and structural interactions. Although earlier rhythm-control strategies failed to demonstrate mortality benefit, largely due to limitations of antiarrhythmic drug therapy, catheter ablation has fundamentally altered the therapeutic landscape.

Recent Findings: The CASTLE-AF trial established catheter ablation as a disease-modifying therapy in patients with AF and HF with reduced ejection fraction (HFrEF), demonstrating reductions in mortality and HF hospitalization. More recently, the CASTLE-HTx trial extended these findings to patients with end-stage HF eligible for heart transplantation (HTx) or left ventricular assist device (LVAD) therapy. Catheter ablation has demonstrated a marked reduction in mortality and the need of an urgent HTx, or LVAD implantation compared with medical therapy alone. Subsequent subanalyses further refined risk stratification and identified patient subsets deriving the greatest benefit. Therefore, catheter ablation has received a class 1 recommendation for patients with AF and HFrEF.

Summary: According to recent clinical evidence supporting early rhythm control through catheter ablation in advanced HF, it leads to a paradigm shift in the management of this high-risk population: in selected patients with AF and advanced HF, clinicians should not delay referral—“Don’t wait, ablate.”

Related

  1. Emotional distress in patients before first-time and redo catheter ablation for atrial fibrillation
    Maja Jabłońska, Bartosz Krzowski, Wojciech Olszewski +11
    BMC Cardiovascular DisordersPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicinePMC
  2. Association between insulin resistance-related indices and the risk of recurrence after catheter ablation in patients with nonvalvular atrial fibrillation.
    Zhaofen Wang, Haijuan Wang, Xiaoxue Guo +2
    Cardiovascular diabetologyPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMCDOAJ
  3. Radiofrequency Catheter Ablation of Atrial Fibrillation in Patients with Anomalous Pulmonary Venous Return: A Multicenter Case Series.
    C. Estrada, O. Baqal, M. Singh Sidhu +6
    medRxivPreprintCC BY-NC-NDFull textCardiovascular medicinemedRxiv
  4. Predictive Value of Left Atrial Strain Combined with Low-Voltage Substrate for Recurrence After Radiofrequency Catheter Ablation in Persistent Atrial Fibrillation
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Radiofrequency ablation with a conventional solid tip catheter in contact with an implantable cardioverter-defibrillator coil causing inadvertent ventricular fibrillation.
    Michael R Manogue
    HeartRhythm case reportsPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{moersdorf2026dont,
  title = {{Don't Wait- Ablate! Catheter Ablation in Patients with Advanced Heart Failure and Atrial Fibrillation}},
  author = {Maximilian Moersdorf and Philipp Sommer and Christian Sohns},
  journal = {Current Heart Failure Reports},
  year = {2026},
  month = oct,
  doi = {10.1007/s11897-026-00787-4},
  url = {https://doi.org/10.1007/s11897-026-00787-4},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Don't Wait- Ablate! Catheter Ablation in Patients with Advanced Heart Failure and Atrial Fibrillation
AU  - Maximilian Moersdorf
AU  - Philipp Sommer
AU  - Christian Sohns
PY  - 2026
DA  - 2026/10/27
JO  - Current Heart Failure Reports
DO  - 10.1007/s11897-026-00787-4
UR  - https://doi.org/10.1007/s11897-026-00787-4
AB  - Purpose of Review: Heart failure (HF) and atrial fibrillation (AF) frequently coexist and mutually accelerate disease progression through complex hemodynamic, neurohormonal, and structural interactions. Although earlier rhythm-control strategies failed to demonstrate mortality benefit, largely due to limitations of antiarrhythmic drug therapy, catheter ablation has fundamentally altered the therapeutic landscape.  Recent Findings: The CASTLE-AF trial established catheter ablation as a disease-modifying therapy in patients with AF and HF with reduced ejection fraction (HFrEF), demonstrating reductions in mortality and HF hospitalization. More recently, the CASTLE-HTx trial extended these findings to patients with end-stage HF eligible for heart transplantation (HTx) or left ventricular assist device (LVAD) therapy. Catheter ablation has demonstrated a marked reduction in mortality and the need of an urgent HTx, or LVAD implantation compared with medical therapy alone. Subsequent subanalyses further refined risk stratification and identified patient subsets deriving the greatest benefit. Therefore, catheter ablation has received a class 1 recommendation for patients with AF and HFrEF.  Summary: According to recent clinical evidence supporting early rhythm control through catheter ablation in advanced HF, it leads to a paradigm shift in the management of this high-risk population: in selected patients with AF and advanced HF, clinicians should not delay referral—“Don’t wait, ablate.”
SN  - 1546-9530
SN  - 1546-9549
ER  -